Psoriasis

 

  • Background

    Pathophysiology

    • Chronic inflammation in the dermis driven by T-cells (Th1 and Th17) and cytokines (IL-12, IL-17, and IL-23) → hyperproliferation of keratinocytes → abnormally rapid growth of epidermis.
    • Plaque psoriasis is the most common manifestation, affecting 90% of psoriasis patients, and is the main focus of this page. Other variants are also described below.

    Epidemiology

    • Prevalence 1/50, with peaks of onset in late teens and late 50s.
    • 1/3 have a family history.

    Triggers

    Flare-ups can be triggered by:

    • Alcohol and smoking.
    • Stress
    • UV light, though sunlight often improves symptoms.
    • Medication: lithium, antimalarials, β-blockers, ACE inhibitors, NSAIDs, steroid withdrawal.
    • Staph. aureus.
  • Signs and symptoms

    Skin lesions:

    • Well-demarcated red plaques (raised areas) covered in white scales.
    • Itchy, though wide variability in severity.
    • No ooze

    Areas affected:

    • Symmetrical
    • Limbs, especially extensor surfaces of knees and elbows.
    • Trunk
    • Palms and soles.
    • On examination, make sure to check behind ears, in scalp, and in umbilicus.

    Nail signs, seen in 50%:

    • Pitting: small indentations.
    • Onycholysis: plate separation. Due to subungual hyperkeratosis.
    • Oil drop sign: yellow-red discolouration.

    Other manifestations:

    • Psoriatic arthritis seen in 15%.
    • Rarely, can develop into erythrodermic or pustular psoriasis.
  • Differential diagnosis

    Eczema:

    • Discoid
    • Seborrheic

    Lichen planus:

    • Purple pruritic papules with thin white lines (Wickham's striae). May coalesce into plaques.
    • Sites: flexor surfaces, palms, soles, wrists, ankles.

    Others:

    • Discoid lupus.
    • Tinea corporis.
  • Management

    1st line: topical therapy

    Regular emollients plus ≥1 of steroids, vitamin A or D analogues, or coal tar. Drug choices:

    • Emollients: options include Diprobase, Epaderm, and E45. Ointments are better than creams for the dry scaly lesions of psoriasis.
    • Corticosteroids: typically used for flares. Betnovate (betamethasone valerate) for trunk and limb (4 weeks); hydrocortisone or Eumovate (clobetasone) for face, flexures, and genitals (2 weeks).
    • Vitamin D analogues – calcipotriol or tacalcitol – usually 1st line for long-term treatment.
    • Vitamin A analogues: dithranol, tazarotene.

    Scalp psoriasis:

    • Mild: coal tar-based shampoo.
    • Severe flare: potent corticosteroid, then scale removal agent (salicylic acid, emollient), then vitamin D analogue.

    Those with extensive disease (>10% body affected), moderate score on Physician's Global Assessment, or nail disease, can be offered 2nd and 3rd line treatment at the same time.

    2nd line: phototherapy

    • 1st line is UVB.
    • 2nd line is PUVA: photosensitizing drug (Psoralen) followed by UVA. Effective but carries cancer risk.

    3rd line: systemic therapy

    • Methotrexate is 1st line.
    • Ciclosporin for flares.
    • Acitretin, a retinoid, if the others are ineffective.
    • Biologics if still unresponsive: ixekizumab, etanercept, infliximab, adalimumab.
  • Flexural psoriasis

    Aka 'inverse psoriasis', due to its inverted distribution relative to plaque psoriasis.

    Distribution:

    • Groin
    • Armpits
    • Umbilicus
    • Natal cleft

    Appearance:

    • Red, shiny and smooth.
    • Less scaly.
  • Guttate psoriasis

    • Small, drop-like papules on trunk, typically 2 weeks after streptococcal pharyngitis.
    • Commoner in young people.
  • Generalised pustular psoriasis

    Pathophysiology

    Sterile pustules (neutrophils) in skin.

    Usually idiopathic, or triggered by:

    • Sudden steroid withdrawal.
    • Drugs e.g. lithium.
    • Topical psoriasis treatments.
    • Infection
    • Pregnancy

    Can be a life-threatening acute form, or a more subacute/chronic disease known as annular pustular psoriasis, which is commoner in children.

    Palmoplantar pustulosis, which resembles a localised form of GPP, is in fact a separate condition.

    Signs and symptoms

    Acute:

    • First sign is red, tender skin.
    • Pustules develop within hours then desquamate.
    • Most commonly affects armpits and anogenital region.
    • Less commonly affects face, tongue, and nails.
    • Systemic symptoms: fever, malaise, nausea.

    Annular pustular psoriasis:

    • Annular (ring-shaped) red plaques with pustules on the periphery.
    • Affects trunk and limbs.
    • Fewer systemic symptoms.

    Management

    • Supportive care including fluids and emollients.
    • Stop causative drugs.
    • Refer to dermatology as systemic therapy often needed: acitretin, methotrexate, or ciclosporin.
  • Erythroderma

    >90% of skin turning red.

    Causes

    • Psoriasis (erythrodermic psoriasis). Usually in a patient with known plaque psoriasis and very rarely is a first presentation. The triggers are similar to those of any psoriasis exacerbation.
    • Eczema
    • Drugs. Many causes, including carbamazepine, phenytoin, vancomycin, and penicillins.
    • Lymphoma
    • Idiopathic

    Symptoms

    Skin:

    • Red, warm, skin.
    • Pain and itch.

    Systemic symptoms and complications:

    • Hypovolaemia from skin failure, sepsis, and high output HF.
    • Poikilothermia: loss of temperature control. Peripheries may be warm but core is cold. Can also be hyperthermic due to impaired sweating: watch for 'fever' not responding to antibiotics.
    • Oedema due to hypoalbuminaemia, reactive oedema, and high output HF.

    Management

    • Establish cause. Stop (and replace) drugs if needed.
    • Fluids
    • Emollients
    • Temperature control in poikilothermia.
    • Monitor for sepsis.
    • Treat oedema with positioning, not diuretics.
  • Calcipotriol

    Mechanism

    Vitamin D3 analogue which alters T cell transcription.

    Use

    • Less messy than dithranol but less effective.
    • Can be prescribed in primary care.

    Side effects

    ↑Ca2+

  • Dithranol

    Mechanism

    Vitamin A analogue which disrupts mitochondria → ↓cell division so ↓hyperkeratosis.

    Formulation

    Comes as a paste.

    Side effects

    • Stains clothes (permanent) and skin (non-permanent).
    • Chemical burn.
  • Coal tar

    Mechanism

    Keratolytic → skin sheds.

    Contraindications

    Broken skin.

    Side effects

    • Irritant
    • Stain
    • Desquamation

Comments

Popular posts from this blog

FCPS Part 1 Preparation: Step-by-Step Guide to Success

FCPS Degree Components: A Complete Roadmap to Specialization

Comprehensive TOACS Stations for FCPS IMM Exam Preparation